Dapagliflozin in STEMI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 256 participants.

Also called NCT06174753

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 256 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06174753
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06174753. Randomized; triple masking; primary purpose treatment. Start 2025-01-20 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin in STEMI
Acronym
DAPA STEMI
Condition
ST Elevation Myocardial Infarction
Intervention (Drug)
Dapagliflozin 10mg Tab
Intervention (Diagnostic test)
CMR
Lead sponsor
Ottawa Heart Institute Research Corporation (class: other)

Record details

Record id
cardio:ct-nct06174753
Content hash
3f55ab840424d681a395fd272fa1d5d13619804c4386729685c0243a71a3bd7c